

May 23, 2024

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Sirs,

Sub: Newspaper Advertisement – Audited Financial Results for the quarter and year ended March 31, 2024

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of newspaper advertisement published on May 23, 2024 in the 'Financial Express' and 'Lokmat' providing extract of the Audited Financial Results of the Company for the quarter and year ended March 31, 2024.

These are also being made available on the Company's website at www.strides.com

This is for your information and record.

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515





Encl. as above

DTD = 23/05/2024

FINANCIAL EXPRESS
(English)

LOK MAT
(MARATHI)

|  Strides Pharma Science Limited CIN : L24230MH1990PLC057062 Registered Office: 201, 'Devavrata', Sector 17, Vashi, Navi Mumbai - 400 703, Maharashtra, India Tel No.: +91 22 2789 2924 ; Fax No.: +91 22 2789 2942 Corporate Office: 'Strides House', Bilekahalli, Bannerghatta Road, Bangalore - 560 076, Karnataka, India Tel No.: +91 80 6784 0000/ 6784 0290 ; Fax No.: +91 80 6784 0800 Website: www.strides.com; Email ID: investors@strides.com | | | | | |
|--|-------------------------------|--|--|--|------------------------------------|
| Extract of the consolidated audited financial results for the quarter and year ended March 31, 2024 | | | | | |
| Particulars | Consolidated | | | | |
| | 3 Months ended March 31, 2024 | Preceding 3 Months ended December 31, 2023 | Corresponding 3 Months ended in the previous year March 31, 2023 | Year to date figures for the period ended March 31, 2024 | Previous year ended March 31, 2023 |
| | AUDITED | UNAUDITED | AUDITED | AUDITED | AUDITED |
| Continuing operations | | | | | |
| Revenue from operations | 10,840.35 | 10,376.68 | 9,863.70 | 40,511.24 | 36,883.87 |
| Net Profit from ordinary activities before Exceptional Items and tax (*) | 862.72 | 720.53 | 412.32 | 2,478.37 | 161.15 |
| Net Profit / (Loss) from ordinary activities before tax from continuing operations | 296.22 | 100.12 | (67.08) | (1,169.44) | (2,862.00) |
| Net Profit/ (Loss) from ordinary activities after tax from continuing operations | 103.71 | (0.90) | (137.95) | (1,485.34) | (2,308.99) |
| Profit/(loss) after tax from discontinued operations | 0.72 | 541.48 | - | 542.20 | 185.69 |
| Total comprehensive income for the period | (428.66) | 601.92 | (645.12) | (1,490.18) | (2,044.14) |
| Equity share capital | 919.00 | 918.86 | 903.03 | 919.00 | 903.03 |
| Other equity | 20,336.63 | - | 21,219.55 | 20,336.63 | 21,219.55 |
| Earnings per equity share (for total operations) (face value of Rs. 10/- each) | (not annualised) | (not annualised) | (not annualised) | (annualised) | (annualised) |
| (a) Basic EPS (Rs.) | 1.98 | 5.43 | (1.06) | (7.76) | (22.49) |
| (b) Diluted EPS (Rs.) | 1.97 | 5.42 | (1.06) | (7.76) | (22.49) |
| (*) The Company did not have Extra-ordinary items for the given periods. | | | | | |
| Information on Standalone Results :- | | | | | |
| Particulars | Rs. in Million | | | | |
| | 3 Months ended March 31, 2024 | Preceding 3 Months ended December 31, 2023 | Corresponding 3 Months ended in the previous year March 31, 2023 | Year to date figures for the period ended March 31, 2024 | Previous year ended March 31, 2023 |
| | AUDITED | UNAUDITED | AUDITED | AUDITED | AUDITED |
| Total Income from continuing operations | 6,472.66 | 5,287.01 | 5,899.35 | 22,255.64 | 19,385.62 |
| Profit/(loss) before Tax from continuing operations | 527.78 | 35.20 | 652.00 | 696.21 | (647.60) |
| Profit/(loss) after Tax from continuing operations | 536.64 | 25.42 | 623.97 | 654.91 | 46.82 |
| Profit/(loss) before tax from discontinued operations | - | - | - | - | - |
| Profit/(loss) after tax from discontinued operations | - | - | - | - | - |
| Notes: | | | | | |
| 1) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites viz., www.nseindia.com & www.bseindia.com and on the Company's website www.strides.com. | | | | | |
| For and on behalf of the Board Sd/- Arun Kumar Executive Chairperson and Managing Director | | | | | |
| Ooty, May 22, 2024 | | | | | |

|  Strides Pharma Science Limited CIN : L24230MH1990PLC057062 Registered Office: 201, 'Devavrata', Sector 17, Vashi, Navi Mumbai - 400 703, Maharashtra, India Tel No.: +91 22 2789 2924 ; Fax No.: +91 22 2789 2942 Corporate Office: 'Strides House', Bilekahalli, Bannerghatta Road, Bangalore - 560 076, Karnataka, India Tel No.: +91 80 6784 0000/ 6784 0290 ; Fax No.: +91 80 6784 0800 Website: www.strides.com; Email ID: investors@strides.com | | | | | |
|--|-------------------------------|--|--|--|------------------------------------|
| Extract of the consolidated audited financial results for the quarter and year ended March 31, 2024 | | | | | |
| Particulars | Consolidated | | | | |
| | 3 Months ended March 31, 2024 | Preceding 3 Months ended December 31, 2023 | Corresponding 3 Months ended in the previous year March 31, 2023 | Year to date figures for the period ended March 31, 2024 | Previous year ended March 31, 2023 |
| | AUDITED | UNAUDITED | AUDITED | AUDITED | AUDITED |
| Continuing operations | | | | | |
| Revenue from operations | 10,840.35 | 10,376.68 | 9,863.70 | 40,511.24 | 36,883.87 |
| Net Profit from ordinary activities before Exceptional Items and tax (*) | 862.72 | 720.53 | 412.32 | 2,478.37 | 161.15 |
| Net Profit / (Loss) from ordinary activities before tax from continuing operations | 296.22 | 100.12 | (67.08) | (1,169.44) | (2,862.00) |
| Net Profit/ (Loss) from ordinary activities after tax from continuing operations | 103.71 | (0.90) | (137.95) | (1,485.34) | (2,308.99) |
| Profit/(loss) after tax from discontinued operations | 0.72 | 541.48 | - | 542.20 | 185.69 |
| Total comprehensive income for the period | (428.66) | 601.92 | (645.12) | (1,490.18) | (2,044.14) |
| Equity share capital | 919.00 | 918.86 | 903.03 | 919.00 | 903.03 |
| Other equity | 20,336.63 | - | 21,219.55 | 20,336.63 | 21,219.55 |
| Earnings per equity share (for total operations) (face value of Rs. 10/- each) | (not annualised) | (not annualised) | (not annualised) | (annualised) | (annualised) |
| (a) Basic EPS (Rs.) | 1.98 | 5.43 | (1.06) | (7.76) | (22.49) |
| (b) Diluted EPS (Rs.) | 1.97 | 5.42 | (1.06) | (7.76) | (22.49) |
| (*) The Company did not have Extra-ordinary items for the given periods. | | | | | |
| Information on Standalone Results :- | | | | | |
| Particulars | Rs. in Million | | | | |
| | 3 Months ended March 31, 2024 | Preceding 3 Months ended December 31, 2023 | Corresponding 3 Months ended in the previous year March 31, 2023 | Year to date figures for the period ended March 31, 2024 | Previous year ended March 31, 2023 |
| | AUDITED | UNAUDITED | AUDITED | AUDITED | AUDITED |
| Total Income from continuing operations | 6,472.66 | 5,287.01 | 5,899.35 | 22,255.64 | 19,385.62 |
| Profit/(loss) before Tax from continuing operations | 527.78 | 35.20 | 652.00 | 696.21 | (647.60) |
| Profit/(loss) after Tax from continuing operations | 536.64 | 25.42 | 623.97 | 654.91 | 46.82 |
| Profit/(loss) before tax from discontinued operations | - | - | - | - | - |
| Profit/(loss) after tax from discontinued operations | - | - | - | - | - |
| Notes: | | | | | |
| 1) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites viz., www.nseindia.com & www.bseindia.com and on the Company's website www.strides.com. | | | | | |
| For and on behalf of the Board Sd/- Arun Kumar Executive Chairperson and Managing Director | | | | | |
| Ooty, May 22, 2024 | | | | | |